Your browser doesn't support javascript.
loading
Recognition of pneumococcal isolates by antisera raised against PspA fragments from different clades.
Darrieux, Michelle; Moreno, Adriana T; Ferreira, Daniela M; Pimenta, Fabiana C; de Andrade, Ana Lúcia S S; Lopes, Alexandre P Y; Leite, Luciana C C; Miyaji, Eliane N.
Afiliación
  • Darrieux M; Centro de Biotecnologia, Instituto Butantan, Av. Vital Brasil, 1500, 05509-900, São Paulo, SP, Brazil.
  • Moreno AT; Centro de Biotecnologia, Instituto Butantan, Av. Vital Brasil, 1500, 05509-900, São Paulo, SP, Brazil.
  • Ferreira DM; Centro de Biotecnologia, Instituto Butantan, Av. Vital Brasil, 1500, 05509-900, São Paulo, SP, Brazil.
  • Pimenta FC; Instituto de Patologia Tropical e Saude Publica, Universidade Federal de Goias, Goiania, Brazil.
  • de Andrade ALSS; Instituto de Patologia Tropical e Saude Publica, Universidade Federal de Goias, Goiania, Brazil.
  • Lopes APY; Centro de Biotecnologia, Instituto Butantan, Av. Vital Brasil, 1500, 05509-900, São Paulo, SP, Brazil.
  • Leite LCC; Centro de Biotecnologia, Instituto Butantan, Av. Vital Brasil, 1500, 05509-900, São Paulo, SP, Brazil.
  • Miyaji EN; Centro de Biotecnologia, Instituto Butantan, Av. Vital Brasil, 1500, 05509-900, São Paulo, SP, Brazil.
J Med Microbiol ; 57(Pt 3): 273-278, 2008 Mar.
Article en En | MEDLINE | ID: mdl-18287288
ABSTRACT
Pneumococcal surface protein A (PspA) is an important vaccine candidate against pneumococcal infections, capable of inducing protection in different animal models. Based on its structural diversity, it has been suggested that a PspA-based vaccine should contain at least one fragment from each of the two major families (family 1, comprising clades 1 and 2, and family 2, comprising clades 3, 4 and 5) in order to elicit broad protection. This study analysed the recognition of a panel of 35 pneumococcal isolates bearing different PspAs by antisera raised against the N-terminal regions of PspA clades 1 to 5. The antiserum to PspA clade 4 was found to show the broadest cross-reactivity, being able to recognize pneumococcal strains containing PspAs of all clades in both families. The cross-reactivity of antibodies elicited against a PspA hybrid including the N-terminal region of clade 1 fused to a shorter and more divergent fragment (clade-defining region, or CDR) of clade 4 (PspA1-4) was also tested, and revealed a strong recognition of isolates containing clades 1, 4 and 5, and weaker reactions with clades 2 and 3. The analysis of serum reactivity against different PspA regions further revealed that the complete N-terminal region rather than just the CDR should be included in an anti-pneumococcal vaccine. A PspA-based vaccine is thus proposed to be composed of the whole N-terminal region of clades 1 and 4, which could also be expressed as a hybrid protein.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Streptococcus pneumoniae / Proteínas Bacterianas / Vacunas Neumococicas / Anticuerpos Antibacterianos Límite: Animals / Female / Humans Idioma: En Revista: J Med Microbiol Año: 2008 Tipo del documento: Article País de afiliación: Brasil

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Streptococcus pneumoniae / Proteínas Bacterianas / Vacunas Neumococicas / Anticuerpos Antibacterianos Límite: Animals / Female / Humans Idioma: En Revista: J Med Microbiol Año: 2008 Tipo del documento: Article País de afiliación: Brasil